Summary of PHARMAC decisions

New listings 

• Calcium carbonate (Calci-Tab 500) tab 1.25 g (500 mg elemental)
• Emicizumab (Hemlibra) inj 30 mg in 1 ml vial, 60 mg in 0.4 ml vial, 105 mg in 0.7 ml vial and 150 mg in 1 ml vial – Xpharm and Special Authority
• Potassium chloride (Juno) inj 75 mg per ml, 10 ml – S29 and wastage claimable
• Pimecrolimus (Elidel) crm 1%, 15 g OP – Special Authority – Retail pharmacy
• Pregnancy test – HCG urine (David One Step Cassette Pregnancy Test) cassette, 40 test OP – up to 200 test available on a PSO and only on a PSO
• Carbimazole (Neo-Mercazole S29) tab 5 mg – S29 and wastage claimable
• Goserelin (Teva) implant 3.6 mg, syringe and implant 10.8 mg, syringe
• Tobramycin (Tobramycin BNM) solution for inhalation 60 mg per ml, 5 ml – subsidy by endorsement and wastage claimable
• Neostigmine metilsulfate (Max Health) inj 2.5 mg per ml, 1 ml ampoule
• Cyclizine lactate (Hameln) inj 50 mg per ml, 1 ml
• Melphalan (Alkeran S29) inj 50 mg – PCT only – Specialist and S29
• Mitomycin C (Teva) inj 20 mg vial – PCT only – Specialist
• Imatinib mesilate (Imatinib-Rex) cap 400 mg
• Travoprost (Mylan) eye drops 0.004%, 5 ml OP – S29
• Pharmacy services (BSF Atomoxetine Generic Partners) brand switch fee – may only be claimed once per patient
• Aminoacid formula without phenylalanine (PKU Anamix Infant) infant formula, 400 g OP – Special Authority – Hospital pharmacy [HP3]

Changes to restrictions

• Hydroxocobalamin (Hydroxocobalamin Mercury Pharma) inj 1 mg per ml, 1 ml ampoule – S29 and wastage removed
• Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe – amended Special Authority criteria
• Escitalopram (Escitalopram-Apotex) tab 10 mg and 20 mg – reinstate stat dispensing
• Moclobemide (Aurorix) tab 300 mg – remove stat dispensing
• Pregabalin (Lyrica) cap 150 mg – S29 and wastage removed
• Sumatriptan (Imigran) inj 12 mg per ml, 0.5 ml prefilled pen – brand switch fee removed
• Prochlorperazine (Nausafix) tab 5 mg – reinstate stat dispensing
• Atomoxetine (Generic Partners) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg – addition of brand switch fee
• Pegaspargase (Oncastar LYO) inj 750 iu per ml, 5 ml vial – amended Special Authority criteria
• Etanercept (Enbrel) inj 25 mg, inj 50 mg autoinjector and prefilled syringe – amended Special Authority criteria
• Adalimumab inj 20 mg per 0.4 ml and 40 mg per 0.8 ml prefilled syringe (Humira) and inj 40 mg per 0.8 ml prefilled pen (HumiraPen) – amended Special Authority criteria
• Rituximab inj 100 mg per 10 ml and 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter (Mabthera)) – amended Special Authority criteria
• Tocilizumab inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial (Actemra) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Dornase alfa (Pulmozyme) nebuliser soln, 2.5 mg per 2.5 ml ampoule – amended Special Authority criteria
• Extensively hydrolysed formula (Aptamil AllerPro SYNEO 1 and Aptamil AllerPro SYNEO 2) – amended brand name

Increased subsidy 

• Mitomycin C (Baxter) inj 1 mg for ECP

Increased price but not subsidy 

• Mupirocin (Bactroban) oint 2%, 15 g OP
• Clobetasone butyrate (Eumovate) crm 0.05%, 30 g OP